The U.S. Food and Drug Administration (FDA) approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce ...
Pfizer has announced the approval of HYMPAVZI by the US Food and Drug Administration (FDA) for patients with haemophilia A ...
Marstacimab is a human monoclonal immunoglobulin G type 1 antibody that enhances coagulation by targeting the Kunitz 2 domain of tissue factor pathway inhibitor.
The FDA granted the approval of Hympavzi to Pfizer Inc.
Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection ...
The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge ...
The drug will be marketed under the trade name Hympavzi. With this nod, the once-weekly Hympavzi is approved for routine prophylaxis (RP) to prevent or reduce the frequency of bleeding episodes in ...
Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...
Pfizer’s Hympavzi receives US FDA approval to treat adults and adolescents with haemophilia A or B without inhibitors: New York Monday, October 14, 2024, 18:00 Hrs [IST] Pfizer ...
Pfizer PFE announced that the FDA has approved its subcutaneously administered drug marstacimab for treating certain ...